Www.biobrand.ba



ENDOCRINOLOGY, DIABETESAND METABOLISM CLINICSARAJEVO Sarajevo, 29/07/2013Prof. Dr. Be?ir Helji?Expert head researcher CARDIO FITUpon the request by BIO BREND D.O.O. JablanicaSUBJECT: Report on the conducted Research of the CARDIO FIT preparationREPORT:The company BIO BREND D.O.O. from Jablanica ordered a prospective study with 500 patients who will be given CARDIO FIT preparation, and who were chosen according to their medicinal indications of lipid status disorder (metabolic lipid disorder). The research began on 10/04/2013 and ended on 26/07/2013. It was conducted in 5 diabetes counsels in Sarajevo, and under the expert guidance of prof. Dr. Be?ir Helji?.A SHORT CV:Prof. Dr. Be?ir Helji? is a regular professor at the Department of Internal Medicine of the Faculty of Medicine in Sarajevo, and the Head of the Endocrinology, Diabetes and Metabolism Clinic. He has written and published six books or chapters in books in the area of internal medicine, has written 112 scientific research articles which were published in indexed journals and presented at conferences and expert symposia. He has participated in 3 International scientific research projects and 6 domestic scientific research projects.This research project plans for the patients’ consumption of CARDIO FIT, in the dosage recommended by the research client for the duration of 5 weeks. All the patients included in the study were chosen on the basis of lipid metabolism disorder. Before their inclusion into the research, all the patients had made a lipid profile, blood sugar test, HbA1c, blood pressure control, EKG, waist circumference and BMI (Body mass index). The patients were familiarized with the usage of CARDIO FIT preparation and received the complete dosage of CARDIO FIT. The control of the same parameters was conducted after 5 weeks.RESULT DISCUSSION:All the patients received CARDIO FIT preparation free of charge during the entire study. 500 patients of all ages were included in the research. Four patients experienced side effects related to their gastrointestinal tracts and decided against further consumption of the preparation (0,8%), eight patients had minor gastrointestinal difficulties and continued to consume half of the recommended dosage of the preparation for 3-5 days after which the difficulties ended and they continued with the full dosage. 14 patients (2,8%) out of the total number of patients did not show up for the control check-up after 5 weeks of consuming the preparation due to unknown reasons, so it may be concluded that out of the 5101590-807085total number of patients included in this research, these 14 may be disregarded in the interpretation of CARDIO FIT’s effectiveness. All the patients have had a registered pre-diabetes status or had diabetes type B, 29% of the patients have never taken statins for dyslipidaemia treatment, and 71% of patients have been taking them occasionally but ceased to take them during the consumption of the CARDIO FIT preparation. The results of the researched parameters at the beginning of CARDIO FIT inclusion and 5 weeks upon the cessation of continuing consumption of CARDIO FIT are shown in detail in the following table:Table 1. Analysed parameters before and after treatment with CardiofitAnalysed parametersNumber of participantsBefore the treatmentAfter the treatmentT-testp-valueAge50059,89+/-9,9gSex50039% M61% FBMI50029,43+/-1,4126,95+/-1,121,70,089Waist circumference500102,65+/-6,3695,47+/-3,542,40,016Blood pressure (mmHg)500150/90130/80Reduced by 14%HbA1c (%)5008,64+/-1,77Glucose on an empty stomach (mmol/l)5006,36+/-2,115,91+/-1,721,90,058Total cholesterol (mmol/l)5006,95+/-0,996,49+/-0,352,560,010LDL cholesterol (mmol/l)5003,75+/-2,223,27+/-0,952,640,008HDL cholesterol (mmol/l)5001,05+/-0,471,11+/-0,211,110,260Triglycerides (mmol/l)5003,71+/-0,672,17+/-0,772,350,019Values are expressed as arithmetic mean +/- SDNote: Obtained results are trademarked by the research MENT ON THE OBTAINED RESULTS FROM THE PRESENTED RESEARCH:The results are clearly shown: age and sex of the patients, as well as biochemical parameters monitored in this research. It is statistically significant to emphasize the influence of CARDIO FIT on a significant reduction of total cholesterol levels, triglycerides in the patients’ blood, and LDL cholesterol. Also, it is necessary to emphasize the reduction of BMI and a pronounced reduction in waist circumference, both of which show a statistically significant reduction. The effectiveness of CARDIO FIT on glycaemic control was not significantly registered; a significant reduction of 14% in blood pressure was registered in comparison to prior registered values of all patients. There was a significant decrease in triglyceride levels which represents an absolute indication for the inclusion of this preparation in the treatment of disorders related to triglyceride levels in patients’ blood.C O N C L U S I O N:CARDIO FIT preparation may be recommended and included in the treatment of lipid metabolism disorders, and has a pronounced positive effect on total cholesterol and triglyceride levels. Also, it has a significant effect on the fats’ depots in the human organism; a significant reduction in waist circumference indicates an effect on the reduction of visceral fats’ depots in the human organism. The decrease in BMI and blood pressure indicates a justified CARDIO FIT inclusion for the treatment of the metabolic syndrome and obesity. CARDIO FIT preparation did not have any reported harmful metabolic effects apart from (0,8%) insignificant gastrointestinal difficulties in 4 patients for which we are unsure whether they were other coincidental gastrointestinal and alimentary disorders.Sarajevo, 29/07/20133304540238760 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download